Valuation : Ocular Therapeutix, Inc.

Market Cap 2.3B 1.98B 1.88B 1.7B 3.2B 220B 3.21B 22.32B 8.58B 112B 8.65B 8.46B 354B P/E 2026 *
-7.04x
P/E 2027 * -7.53x
Enterprise Value 1.93B 1.66B 1.57B 1.42B 2.67B 184B 2.69B 18.66B 7.18B 93.6B 7.23B 7.07B 296B EV / Sales 2026 *
36.4x
EV / Sales 2027 * 21.8x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ocular Therapeutix, Inc.

1 day-1.22%
1 week-1.41%
1 month+2.54%
3 months+17.34%
6 months+18.26%
Current year-13.59%
1 week 10.36
Extreme 10.365
11.48
1 month 9.68
Extreme 9.68
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 2024-04-14
Director of Finance/CFO 50 2026-01-19
Chief Tech/Sci/R&D Officer 49 2024-05-19
Director TitleAgeSince
Chairman 57 2019-06-30
Director/Board Member 78 2012-11-04
Director/Board Member 66 2019-03-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Sell

Chief Operating Officer

-1,099 0.0005%
8/25/26 Don

Chief Executive Officer

-100,184 0.0473%
8/24/26 Sell

Executive/Senior Manager

-3,035 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-1.41%-18.11%+186.61% 2.3B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.78%-5.32%+18.06%+54.97% 350.71B
Weighted average by Cap. -0.51%-4.41%+30.93%+55.03%

Financials

2026 *2027 *
Net sales 52.93M 45.6M 43.18M 39.14M 73.42M 5.06B 73.8M 513M 197M 2.57B 199M 194M 8.13B 102M 88.29M 83.6M 75.78M 142M 9.79B 143M 993M 382M 4.98B 385M 376M 15.74B
Net income -334M -288M -273M -247M -464M -31.94B -466M -3.24B -1.25B -16.25B -1.26B -1.23B -51.34B -324M -280M -265M -240M -450M -30.99B -452M -3.14B -1.21B -15.77B -1.22B -1.19B -49.82B
Net Debt -378M -326M -308M -280M -524M -36.11B -527M -3.66B -1.41B -18.37B -1.42B -1.39B -58.05B -66M -56.87M -53.84M -48.8M -91.56M -6.31B -92.02M -640M -246M -3.21B -248M -242M -10.14B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
26-09-11 US$10.49 -1.22% 2,638,751
26-09-10 US$10.62 -7.41% 2,391,778
26-09-09 US$11.47 +0.88% 2,804,776
26-09-08 US$11.37 +6.86% 2,737,328
26-09-04 US$10.64 0.00% 1,306,871
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.49USD
Average target price
27.09USD
Spread / Average Target
+158.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!